IT1394860B1 - Composti farmaceutici - Google Patents

Composti farmaceutici

Info

Publication number
IT1394860B1
IT1394860B1 ITMI2009A001296A ITMI20091296A IT1394860B1 IT 1394860 B1 IT1394860 B1 IT 1394860B1 IT MI2009A001296 A ITMI2009A001296 A IT MI2009A001296A IT MI20091296 A ITMI20091296 A IT MI20091296A IT 1394860 B1 IT1394860 B1 IT 1394860B1
Authority
IT
Italy
Prior art keywords
pharmaceutical compounds
pharmaceutical
compounds
Prior art date
Application number
ITMI2009A001296A
Other languages
English (en)
Inventor
Paolo Lazzari
Matteo ZANDA
Monica Sani
Original Assignee
Kemotech S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kemotech S R L filed Critical Kemotech S R L
Priority to ITMI2009A001296A priority Critical patent/IT1394860B1/it
Priority to ES10169507.0T priority patent/ES2524800T3/es
Priority to EP10169507.0A priority patent/EP2292639B1/en
Priority to JP2010162880A priority patent/JP5959140B2/ja
Priority to CA2710693A priority patent/CA2710693A1/en
Priority to US12/841,976 priority patent/US8580820B2/en
Publication of ITMI20091296A1 publication Critical patent/ITMI20091296A1/it
Application granted granted Critical
Publication of IT1394860B1 publication Critical patent/IT1394860B1/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ITMI2009A001296A 2009-07-22 2009-07-22 Composti farmaceutici IT1394860B1 (it)

Priority Applications (6)

Application Number Priority Date Filing Date Title
ITMI2009A001296A IT1394860B1 (it) 2009-07-22 2009-07-22 Composti farmaceutici
ES10169507.0T ES2524800T3 (es) 2009-07-22 2010-07-14 Derivados de la tubulisina como fármacos anticancerosos
EP10169507.0A EP2292639B1 (en) 2009-07-22 2010-07-14 Tubulisine derivatives as anticancer drugs
JP2010162880A JP5959140B2 (ja) 2009-07-22 2010-07-20 医薬組成物
CA2710693A CA2710693A1 (en) 2009-07-22 2010-07-21 Pharmaceutical compositions
US12/841,976 US8580820B2 (en) 2009-07-22 2010-07-22 Tubulysin compounds with high cytotoxicity, pharmaceutical compositions thereof, and method of use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI2009A001296A IT1394860B1 (it) 2009-07-22 2009-07-22 Composti farmaceutici

Publications (2)

Publication Number Publication Date
ITMI20091296A1 ITMI20091296A1 (it) 2011-01-23
IT1394860B1 true IT1394860B1 (it) 2012-07-20

Family

ID=41800551

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI2009A001296A IT1394860B1 (it) 2009-07-22 2009-07-22 Composti farmaceutici

Country Status (6)

Country Link
US (1) US8580820B2 (it)
EP (1) EP2292639B1 (it)
JP (1) JP5959140B2 (it)
CA (1) CA2710693A1 (it)
ES (1) ES2524800T3 (it)
IT (1) IT1394860B1 (it)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5149620B2 (ja) 2004-07-23 2013-02-20 エンドサイト，インコーポレイテッド ２価リンカーおよびその結合体
NZ580132A (en) 2007-03-14 2012-11-30 Endocyte Inc Binding ligand linked drug delivery conjugates of tubulysins to vitamins
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
CN104383553A (zh) 2007-06-25 2015-03-04 恩多塞特公司 含有亲水性间隔区接头的共轭物
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
EP3210627B1 (en) 2012-07-12 2022-12-21 Hangzhou Dac Biotech Co., Ltd Conjugates of cell binding molecules with cytotoxic agents
JP2015536323A (ja) 2012-10-16 2015-12-21 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 非天然アミノ酸を含む薬物送達結合体および使用方法
AU2012395148B2 (en) 2012-11-24 2016-10-27 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
LT2956173T (lt) * 2013-02-14 2017-06-26 Bristol-Myers Squibb Company Tubulizino junginiai, gavimo ir panaudojimo būdai
FI3122757T3 (fi) 2014-02-28 2023-10-10 Hangzhou Dac Biotech Co Ltd Varautuneita linkkereitä ja niiden konjugointikäyttötapoja
UY36075A (es) * 2014-04-11 2015-10-30 Medimmune Llc Derivados de tubulisina
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
EA201791896A1 (ru) * 2015-02-25 2018-02-28 Уильям Марш Райс Юниверсити Дезацетокситубулизин н и его аналоги
EP3319936B1 (en) 2015-07-12 2025-12-17 Hangzhou Dac Biotech Co., Ltd. Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
TWI852735B (zh) 2015-12-04 2024-08-11 美商思進公司 四級胺化妥布賴森(tubulysin)化合物之結合物
KR102775461B1 (ko) 2016-04-01 2025-02-28 어비디티 바이오사이언시스 인크. 핵산-폴리펩타이드 조성물 및 이의 용도
US10106560B2 (en) 2016-06-16 2018-10-23 Bristol-Myers Squibb Company Process and intermediates for making tubulysin analogs
AU2016429272A1 (en) 2016-11-14 2019-05-02 Hangzhou Dac Biotech Co., Ltd. Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
CN107459532B (zh) * 2017-05-11 2019-05-28 重庆南松凯博生物制药有限公司 一种新的抗癌药物中间体
US20230002440A1 (en) * 2018-09-07 2023-01-05 Seattle Genetics, Inc. Alternative processes for the preparation of tubulysins and intermediates thereof
WO2020102777A1 (en) 2018-11-16 2020-05-22 Virtuoso Binco, Inc. Cd38 and icam1 antibodies and uses thereof
CN118027137A (zh) * 2018-12-21 2024-05-14 里珍纳龙药品有限公司 微管溶素及蛋白质-微管溶素偶联物
IL319265A (en) 2018-12-21 2025-04-01 Avidity Biosciences Inc Anti-transferrin receptor antibodies and their uses
JP2022540395A (ja) 2019-06-29 2022-09-15 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． 細胞結合性分子－チューブリシン誘導体共役体及びその調製方法
WO2021188390A1 (en) 2020-03-19 2021-09-23 Avidity Biosciences, Inc. Compositions and methods of treating facioscapulohumeral muscular dystrophy
WO2021195469A1 (en) 2020-03-27 2021-09-30 Avidity Biosciences, Inc. Compositions and methods of treating muscle dystrophy
CN111647040B (zh) * 2020-05-11 2022-02-22 深圳市老年医学研究所 一种天然活性多肽Tubulysin U的制备方法
MX2024003266A (es) 2021-09-16 2024-04-03 Avidity Biosciences Inc Composiciones y metodos de tratamiento de la distrofia muscular facioescapulohumeral.
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2741621B1 (fr) 1995-11-23 1998-02-13 Sanofi Sa Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
DE19638870B4 (de) 1996-09-23 2009-05-14 Helmholtz-Zentrum für Infektionsforschung GmbH Tubulysine, Verfahren zu ihrer Gewinnung und sie enthaltende Mittel
FR2761266B1 (fr) 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
DK1523493T3 (da) 2002-07-09 2013-12-02 Alexander Doemling Nye tubulysinanaloge
WO2004005326A2 (de) * 2002-07-09 2004-01-15 Morphochem Aktiengellschaft Fu Tubulysinkonjugate
DE10254439A1 (de) * 2002-11-21 2004-06-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Tubulysine, Herstellungsverfahren und Tubulysin-Mittel
CA2593964A1 (en) 2004-12-23 2006-06-29 Molmed Spa Conjugation product
WO2008013861A2 (en) * 2006-07-27 2008-01-31 Redpoint Bio Corporation Screening assay for inhibitors of trpa1 activation by a lower alkyl phenol
NZ580132A (en) * 2007-03-14 2012-11-30 Endocyte Inc Binding ligand linked drug delivery conjugates of tubulysins to vitamins
EP2532673A3 (en) * 2007-05-10 2014-01-08 R & D Biopharmaceuticals Gmbh Tubulysine derivatives
WO2009012958A2 (en) 2007-07-20 2009-01-29 Helmholtz-Zentrum für Infektionsforschung GmbH Tubulysin d analogues
WO2009055562A1 (en) * 2007-10-25 2009-04-30 Endocyte, Inc. Tubulysins and processes for preparing
US8394922B2 (en) * 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof

Also Published As

Publication number Publication date
EP2292639B1 (en) 2014-09-03
ITMI20091296A1 (it) 2011-01-23
JP5959140B2 (ja) 2016-08-02
CA2710693A1 (en) 2011-01-22
EP2292639A1 (en) 2011-03-09
ES2524800T3 (es) 2014-12-12
US20110200581A1 (en) 2011-08-18
JP2011037846A (ja) 2011-02-24
US8580820B2 (en) 2013-11-12

Similar Documents

Publication Publication Date Title
SMT201700008B (it) Composizione farmaceutica
DK3097925T3 (da) Farmaceutisk sammensætning
BRPI1004940A2 (pt) composição farmacêutica
IL245328A0 (en) Pharmaceutical composition
SMT201700095B (is) Composizioni farmaceutiche per inalazione
SMT201400069B (it) Formulazione farmaceutica
BRPI0920521A2 (pt) combinação farmacêutica
DK2427449T3 (da) Vinylindazolylforbindelser
BR112012006859A2 (pt) compostos
BRPI1012539A2 (pt) composições farmacêuticas
BRPI1015939A2 (pt) composição farmacêutica
DK2397480T3 (da) Diazepindionderivat
EE201300005A (et) Ravimkoostis
DK2391349T3 (da) Farmaceutisk sammensætning omfattende 2-oco-1-pyrrolidin-derivater
BRPI1016190A2 (pt) compostos farmacêuticos.
IT1394400B1 (it) Composizioni farmaceutiche
IT1393930B1 (it) Composti farmaceutici
BR112012000831A2 (pt) compostos, composições farmacêuticas e métodos relacionados
DK2387580T3 (da) Deoxyactagardinderivater
BRPI0922653A2 (pt) preparação farmacêutica
DK2271618T3 (da) Farmaceutiske forbindelser
BR112013008074A2 (pt) combinações farmacêuticas
BR112012003149A2 (pt) composição farmacêutica
BR112012001340A2 (pt) composições farmacêuticas
BRPI1006076A2 (pt) composicoes farmaceuticas